Silkim Pharma

Company Overview

Snapshot

Founded in March 2013 by Dror Chevion and Prof. Mordechai (Mottie) Chevion, Silkim Pharma operates with 1–10 employees. The company recently received a positive response and guidance from the FDA regarding its pre-Investigational New Drug (PIND) meeting request for CORONZOT, a drug candidate for COVID-19 treatment.

Business overview

Silkim Pharma is a pharmaceutical company focused on developing novel drugs for inflammatory pathologies. The company's platform, derived from extensive investigation of animal models of human diseases, produces agents with potent anti-inflammatory, iron-chelating, and antibiotic properties. These multi-modal drugs are designed to treat the causes and symptoms of various indications, serving the pharmaceutical and life sciences sectors within the broader Health Tech & Life Sciences industry.

Strategic signal

In May 2020, Silkim Pharma received a positive response and guidance from the FDA for its pre-Investigational New Drug (PIND) meeting request concerning CORONZOT, a drug candidate targeting COVID-19. This development is significant as it validates the potential of Silkim Pharma's novel drug mechanism, which addresses the exaggerated immune system reaction in COVID-19 patients through iron sequestration and the introduction of gallium or zinc ions. The FDA's guidance signals a clear path forward for the company's planned clinical studies and an upcoming IND application, indicating strong regulatory confidence and accelerating its trajectory in developing treatments for critical global health challenges.

Company Intelligence Q&A

What was the key regulatory milestone achieved by Silkim Pharma in May 2020?

In May 2020, Silkim Pharma received a positive response and guidance from the FDA regarding its pre-Investigational New Drug (PIND) meeting request for CORONZOT, a drug candidate aimed at treating COVID-19 patients.

Who are the founders of Silkim Pharma?

Silkim Pharma was co-founded by Dror Chevion and Prof. Mordechai (Mottie) Chevion.

What is the primary focus of Silkim Pharma's drug development platform?

Silkim Pharma's drug development platform focuses on creating novel treatments for inflammatory pathologies, utilizing agents with anti-inflammatory, iron-chelating, and antibiotic properties.

What is the mechanism of action for Silkim Pharma's drug candidate CORONZOT?

CORONZOT employs a novel mechanism based on the sequestration of labile iron and introduces an ion of gallium or zinc to address the exaggerated immune system reaction caused by the coronavirus.

When was Silkim Pharma founded?

Silkim Pharma was founded in March 2013.